CNRT Overview Video References

+ Expand all

  1. Raskin P, Cincotta AH. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
    Expert Review of Endocrinology & Metabolism 2016;11(2):113-48.
  2. Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Reviews. 1996;4(4):464-87.
  3. Cincotta A. Hypothalamic role in Insulin Resistance and insulin Resistance Syndrome. Frontiers in Animal Diabetes Research Series. Taylor and Francis, Eds Hansen, B Shafrir, E London, pp 271-312, 2002
  1. Seasonal variations of severe hypoglycemia in patients with type 1 diabetes mellitus, type 2 diabetes mellitus, and non-diabetes mellitus: clinical analysis of 578 hypoglycemia cases. Tsujimoto T et al. Medicine (Baltimore) 2014;93:e148
  2. Seasonal variation of HbA1c in intensive treatment of children with type 1 diabetes. Nordfeldt S et al. J Pediatr Endocrinol Metab 2000;13:529-35.
  3. Seasonal fluctuations of glycated hemoglobin levels in Japanese diabetic patients. Sakura H et al. Diabetes Res Clin Pract 2010;88:65-70
  4. Seasonal changes in preprandial glucose, A1C, and blood pressure in diabetic patients. Liang WW. Diabetes Care 2007;30:2501-2
  5. Seasonal variation of glycemic control in type 2 diabetic patients. Ishii H et al. Diabetes Care 2001;24:1503
  6. Seasonal changes in body composition and blood HbA1c levels without weight change in male patients with type 2 diabetes treated with insulin. Sohmiya M et al. Diabetes Care 2004;27:1238-9
  7. Seasonal variation in fasting glucose and HbA1c in patients with type 2 diabetes. Gikas A et al. Prim Care Diabetes. 2009;3:111-4
  8. During winter the body resists insulin. Partonen T. Hypertens Res 2013;36:390-1
  9. Association of seasonal variation in the prevalence of metabolic syndrome with insulin resistance.
  10. Kamezaki F et al. Hypertens Res 2013;36:398-402
  11. Seasonal variation in metabolic syndrome prevalence. Kamezaki F et al. Hypertens Res 2010;33:568-72
  12. Seasonal changes in mood and behavior are linked to metabolic syndrome. Rintamäki R et al. PLoS One. 2008;3(1):e1482.
  1. Brain dopamine and obesity. Wang GJ, et al. Lancet. 2001;357(9253):354-7.
  2. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review.
    Wang GJ, et al. J Addict Dis. 2004;23(3):39-53.
  3. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
    Blum K, et al. Theor Biol Med Model. 2008 Nov 12;5:24.
  4. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele.
    Stice E, et al. Science. 2008;322(5900):449-52.
  5. Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Volkow ND, et al. Neuroimage. 2008;42(4):1537-43.
  6. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes.
    Barnard ND, et al. Nutrition. 2009;25(1):58-65.
  7. Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity. Dunn JP, et al. Diabetes Care. 2012;35:1105–1111.
  8. Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy non-obese humans. Caravaggio F, et al. Int J Neuropsychopharmacol. 2015;18(7):pyv014.
  9. Striatal dopamine regulates systemic glucose metabolism in humans and mice. Ter Horst KW, et al. Sci Transl Med. 2018;10(442)pii:eaar3752.
  1. Brain dopamine and obesity. Wang GJ et al. Lancet. 2001;357(9253):354-7.
  2. Comparative effects of the antipsychotics sulpiride or risperidone in rats: bodyweight, food intake, body composition, hormones and glucose tolerance. Baptista T et al. Brain Res. 2002;957(1):144-51.
  3. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Koro CE et al. BMJ. 2002;325(7358):243.
  4. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Leslie DL et al. Am J Psychiatry. 2004;161(9):1709-11.
  5. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Henderson DC et al. Am J Psychiatry. 2000;157(6):975-81.
  6. Pharmacology of antipsychotics in the elderly: a focus on atypicals. Finkel S. J Am Geriatr Soc 2004; 52(12):S258–265
  7. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Tataranni PA et al. Diabetes. 2001;50(4):901-4.
  8. Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Epstein LH et al. Am J Clin Nutr. 2004;80(1):82-8.
  9. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Jenkinson CP et al. Int J Obes Relat Metab Disord. 2000;24(10):1233-8
  10. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Hanson RL et al. Am J Hum Genet. 1998;63(4):1130-8.
  11. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Noble EP et al. Arch Gen Psychiatry. 1991;48(7):648-54.
  12. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Comings DE et al. Mol Psychiatry. 1996;1(4):325-35.
  13. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Blum K et al. Pharmacogenetics. 1996;6(4):297-305.
  14. Variant alleles of the D2 dopamine receptor gene and obesity. Spitz MR et al. Nutrition Research. 2000;20(3):371-380.
  15. Modulation of blood pressure and obesity with the dopamine D2 receptor gene TaqI polymorphism. Thomas GN et al. Hypertension. 2000;36(2):177-82.
  1. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Anderson EA ,et al. Hypertension. 1992;19(6 Pt 2):621-7.
  2. The sympathetic nervous system in hypertension and renal disease. Saruta T, Kumagai H. Curr Opin Nephrol Hypertens. 1996;5(1):72-9.
  3. Role of sympathetic nervous system in hypertension and effects of cardiovascular drugs. Noll G, et al. Eur Heart J. 1998;19(Suppl F):F32-8.
  4. Basal sympathetic nerve activity is enhanced with augmentation of baroreceptor reflex in Wistar fatty rats:
    a model of obesity-induced NIDDM. Suzuki H, et al. J Hypertens. 1999;17(7):959-64.
  5. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Hall JE, et al. Braz J Med Biol Res. 2000;33(6):605-18.
  6. Insulin resistance and the sympathetic nervous system. Egan BM. Curr Hypertens Rep. 2003;5(3):247-54.
  7. Elevated sympathetic nerve activity: the link between low birth size and adult-onset metabolic syndrome?
    Hausberg M, et al. J Hypertens. 2004;22(6):1087-9.
  8. High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Aso Y, et al. Metabolism. 2006;55(8):1014-21.
  9. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Grassi G. Hypertens Res. 2006;29(11):839-47.
  10. Insulin resistance and sympathetic overactivity in women. Kaaja RJ, Pöyhönen-Alho MK. J Hypertens. 2006;24(1):131-41.
  11. Sympathetic system activity in obesity and metabolic syndrome. Tentolouris N, et al. Ann N Y Acad Sci. 2006;1083:129-52.
  12. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Grassi G, et al. Nutr Metab Cardiovasc Dis. 2007;17(6):473-81.
  13. The sympathetic nervous system and the metabolic syndrome. Mancia G, et al. J Hypertens. 2007;25(5):909-20.
  14. Mediators of sympathetic activation in metabolic syndrome obesity. Straznicky NE, et al. Curr Hypertens Rep. 2008;10(6):440-7.
  15. Increased sympathetic reactivity may predict insulin resistance: an 18-year follow-up study. Flaa A, et al. Metabolism. 2008;57(10):1422-7.
  16. The role of norepinephrine and insulin resistance in an early stage of hypertension. Penesova A, et al. Ann N Y Acad Sci. 2008;1148:490-4.
  17. Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure.
    Lambert E, et al. J Hypertens. 2010;28(3):543-50.
  18. Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.
    Lambert GW, et al. Pharmacol Ther. 2010;126(2):159-72.
  19. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.
    Masuo K, et al. Curr Diabetes Rev. 2010 Mar;6(2):58-67.
  20. Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome. Lambert EA, Curr Hypertens Rep. 2011;13(3):244-8.
  21. Increased visceral adipose tissue is associated with increased resting heart rate in patients with manifest vascular disease.
    Bemelmans RH et al. Obesity (Silver Spring). 2012;20(4):834-41.
  22. Risk of elevated resting heart rate on the development of type 2 diabetes in patients with clinically manifest vascular diseases.
    Bemelmans RH, et al. Eur J Endocrinol. 2012;166(4):717-25.
  23. Leptin increasing sympathetic nerve outflow in obesity: A cure for obesity or a potential contributor to metabolic syndrome?
    Simonds SE, et al. J. Adipocyte. 2012;1(3):177-181.
  24. Obesity and adipokines: effects on sympathetic overactivity. Smith MM, Minson CT. J Physiol. 2012;590(8):1787-801.
  25. The risk of resting heart rate on vascular events and mortality in vascular patients. Bemelmans RH, et al. Int J Cardiol. 2013;168(2):1410-5.
  26. Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity. Canale MP, et al. Int J Endocrinol. 2013;2013:865965.
  27. Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Thorp AA, Schlaich MP. J Diabetes Res. 2015;2015:341583.